Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation: Heart Failure
Search: search_blue_button Advanced Search
Circulation: Heart Failure. 2008;1:9-16
doi: 10.1161/CIRCHEARTFAILURE.108.767483
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Yancy, C. W.
PubMed
Right arrow Articles by Yancy, C. W.
Related Collections
Right arrow Congestive

Original Articles

Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure

Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial

Clyde W. Yancy, MD; Henry Krum, MD; Barry M. Massie, MD; Marc A. Silver, MD; Lynne Warner Stevenson, MD; Mei Cheng, PhD; Sun Sook Kim, MS, RAC; Rosemary Evans, MD, MPH for the FUSION II Investigators

From Baylor University Medical Center, Heart and Vascular Institute, Dallas, Tex (C.W.Y.); Monash University and Alfred Hospital, Melbourne, Victoria, Australia (H.K.); University of California at San Francisco and Veterans Administration Medical Center, San Francisco, Calif (B.M.M.); Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, Ill (M.A.S.); Brigham and Women’s Hospital Cardiovascular Division, Advanced Heart Disease Section, Boston, Mass (L.W.S.); and Scios Inc, Fremont, Calif (M.C., S.S.K., R.E.).

Correspondence to Clyde W. Yancy, MD, Baylor University Medical Center, Baylor Heart and Vascular Institute, 3500 Gaston Ave, Suite H 030, Dallas, TX 75246. E-mail clydey{at}baylorhealth.edu

Received January 17, 2008; accepted February 5, 2008.

Background— Patients with American College of Cardiology/American Heart Association stage C/D heart failure experience substantial morbidity and mortality, but available interventions beyond standard medical and device therapies are limited. Nesiritide relieves dyspnea and reduces pulmonary congestion, but its risk profile is uncertain. Pilot data suggested a potential benefit of nesiritide given as serial outpatient infusions.

Methods and Results— The Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial was a randomized, double-blind, placebo-controlled trial of outpatient serial nesiritide infusions for patients with American College of Cardiology/American Heart Association stage C/D heart failure. Patients with 2 recent heart failure hospitalizations, ejection fraction <40%, and New York Heart Association class IV symptoms, or New York Heart Association class III symptoms with creatinine clearance <60 mL/min, were randomized to nesiritide (2-µg/kg bolus plus 0.01-µg/kg-per-minute infusion for 4 to 6 hours) or matching placebo, once or twice weekly for 12 weeks. All patients were treated to optimal goals with evidence-based medical/device therapy facilitated by careful disease management during the study. The primary end point was time to all-cause death or cardiovascular or renal hospitalization at 12 weeks. A total of 911 patients were randomized and treated. The primary end point occurred in 36.8% and 36.7% of the placebo and nesiritide groups, respectively (hazard ratio, 1.03; 95% confidence interval, 0.82 to 1.3; log-rank test P=0.79). There were no statistically significant differences between groups in any of the secondary end points, including the number of cardiovascular or renal hospitalizations, the number of days alive and out of the hospital, change in Kansas City Cardiomyopathy Questionnaire score, or cardiovascular death. Adverse events were similar between groups; nesiritide was associated with more hypotension but less predefined worsening renal function.

Conclusions— Serial outpatient nesiritide infusions do not provide a demonstrable clinical benefit over intensive outpatient management of patients with advanced American College of Cardiology/American Heart Association stage C/D heart failure.

Key Words: heart failure • kidney • natriuretic peptides


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Journal Watch CardiologyHome page
Nesiritide Infusion Comes Up Short Again
Journal Watch Cardiology, June 11, 2008; 2008(611): 2 - 2.
[Full Text]


Home page
Circ Heart FailHome page
J. C. Burnett Jr and J. Korinek
The Tumultuous Journey of Nesiritide: Past, Present, and Future
Circ Heart Fail, May 1, 2008; 1(1): 6 - 8.
[Full Text] [PDF]